جستجوی استاد راهنمای دانشگاهی

James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.

• Microbiology
• Immunology
• Bacterial Vaccines
• +۵ مورد دیگر

Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.

• AI for drug discovery
• Generative AI models
• Geometric deep learning
• +۵ مورد دیگر

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +۷ مورد دیگر

Paul O'Toole is a Professor of Microbial Genomics and Principal Investigator at the APC Microbiome Ireland, University College Cork. His research focuses on the gut microbiome's role in health, aging, and disease, particularly in the context of diet and probiotics. He leads projects like the ELDERMET study on elderly nutrition and the NU-AGE project exploring Mediterranean diets' anti-aging effects. He holds a BA (Mod.) from Trinity College Dublin and a PhD from Lund University, with postdoctoral training in Canada and New Zealand. Key grants include studies on dairy-derived microbiota, probiotic strain improvement, and microbiome analysis in aging populations. He has published extensively on Lactobacillus genomics, gut-brain interactions, and microbiome-driven health outcomes. His work bridges fundamental microbiology with clinical applications, emphasizing translational research. Scientific highlights include discovering microbiome links to cognitive decline, demonstrating dietary modulation of gut microbes to combat obesity, and identifying keystone species in healthy aging. He advocates for sustainability in conservation and food systems, reflecting his interdisciplinary approach to global health challenges.

• Microbial Genomics
• Gut Microbiome
• Aging and Healthy Aging
• +۴ مورد دیگر

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

• Biochemistry
• Systems Biology
• Biological Regulation
• +۸ مورد دیگر

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +۵ مورد دیگر

Michele Klingbeil is a Professor in the Department of Microbiology at the University of Massachusetts Amherst, where she leads the Klingbeil DNA Replication Laboratory. She received her PhD in Cell and Molecular Biology from the University of Toledo in 1996 and previously worked at Johns Hopkins School of Medicine before moving to UMass in July 2007. Her educational background includes: PhD in Cell and Molecular Biology, University of Toledo, 1996 Dr. Klingbeil's research focuses on the unique biology of trypanosomatid parasites, particularly Trypanosoma brucei , the causative agent of African sleeping sickness. Her laboratory investigates two main areas: (1) replication of the unusual mitochondrial DNA network called kinetoplast DNA (kDNA), and (2) nuclear DNA replication initiation. Her work on kDNA is particularly significant as this structure is essential for parasite survival but has no counterpart in mammalian hosts, making it an attractive drug target. She employs a combination of reverse genetics (RNAi), cell biology, and biochemistry to understand the replication and repair mechanisms of kDNA, with a special focus on a family of four DNA polymerases related to bacterial Pol I. Dr. Klingbeil's recent publications reveal her laboratory's deep investigation into mitochondrial DNA polymerases in trypanosomatids, with discoveries showing multiple polymerases having specialized functions in kDNA replication and repair. Her research has established that several of these polymerases are essential for parasite viability, opening new avenues for drug development. She has also made significant contributions to understanding the simplified Origin Recognition Complex in trypanosomatids compared to other eukaryotes. Dr. Klingbeil has received the Thomas G. Lessie Distinguished Lectureship Award for her impact on teaching at the graduate level. Her research is funded by the National Institutes of Health, U.S. Department of Agriculture, the Joeph P. Healey Endowment, and the University of Massachusetts Amherst. She has mentored numerous graduate and undergraduate students, including current PhD candidates Dave Bruhn, Jeniffer Concepción, and Juemin Luo, as well as visiting scholar Eva Vidal Rico. Her former students have gone on to positions at institutions including Dana Farber/Broad Institute, Regis College, and Flagship Ventures. The laboratory regularly participates in scientific conferences including the Molecular Parasitology Meeting at Woods Hole and the Kinetoplastid Molecular Cell Biology conference. Dr. Klingbeil teaches several courses including Parasitology (MICRO 590S), Parasitology Lab (MICRO 590L), Molecular Mechanisms of Pathogenesis (MICRO 797P), Advanced Cell Biology (MCB 641), and Writing in Microbiology (MICRO 360). Her laboratory organizes regular social events including pumpkin carving parties and outings to Six Flags New England and Mt. Sugarloaf.

• Parasitology
• Molecular Biology
• Microbiology
• +۴ مورد دیگر

Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.

• Chemical Biology
• Chromatin Modification
• Enzymology
• +۳ مورد دیگر

Patricia Champion is a Professor in the Department of Biological Sciences at the University of Notre Dame, where she holds the title of Notre Dame Collegiate Professor. Her research is centered on the molecular mechanisms of mycobacterial pathogenesis, with a focus on protein transport and virulence. She is affiliated with the Eck Institute for Global Health and the Center for Rare and Neglected Diseases. PhD in Molecular Biology, Princeton University (2003) B.S. in Biological Sciences, Carnegie Mellon University (1998) Her research interests lie in understanding how pathogenic mycobacteria, including Mycobacterium tuberculosis and M. marinum , cause disease through targeted protein secretion, particularly via the Type VII (ESX-1) secretion system. She investigates how secreted proteins function as effectors and regulate gene expression, and how post-translational modifications like acetylation influence virulence. Her lab employs an interdisciplinary approach combining genetics, molecular biology, proteomics, and transcriptomics. The recent publications highlight a strong focus on ESX-1-mediated secretion, identification of novel substrates, regulatory mechanisms (e.g., WhiB6, EspM), and post-translational modifications. The work spans fundamental bacterial physiology to host-pathogen interactions, contributing to the broader goal of identifying targets for anti-virulence therapeutics against tuberculosis. Her scientific recognition includes being named a Notre Dame Collegiate Professor, a distinguished honor reflecting her scholarly excellence. Dr. Champion leads an active research laboratory committed to fostering an inclusive and respectful environment, emphasizing core values such as integrity, teamwork, and excellence. Her lab's work is supported by ongoing research grants, though specific funding sources are not detailed in the text. The Champion Lab operates within the Department of Biological Sciences and collaborates with key institutes at Notre Dame focused on global and neglected diseases.

• Molecular Genetics
• Mycobacterial Pathogenesis
• Bacterial Genetics
• +۷ مورد دیگر

Pinar Keskinocak serves as the H. Milton and Carolyn J. Stewart School Chair and Professor in the H. Milton Stewart School of Industrial and Systems Engineering at the Georgia Institute of Technology. She co-founded and directs the Center for Health and Humanitarian Systems, demonstrating leadership in both academic administration and research innovation. Her career includes prior roles as College of Engineering ADVANCE Professor and interim associate dean for faculty development, alongside industry experience at IBM T.J. Watson Research Center. Her educational foundation includes a Ph.D. in Operations Research from Carnegie Mellon University and M.S. and B.S. degrees in Industrial Engineering from Bilkent University. This rigorous training underpins her interdisciplinary approach to complex societal challenges. Dr. Keskinocak's research pioneers operations research applications for societal impact , with dual emphases on health systems and humanitarian logistics . She develops advanced models for infectious disease dynamics (including COVID-19, malaria, and Guinea worm), vaccination strategies, disaster response, and supply chain optimization. Her work uniquely bridges engineering analytics with real-world implementation through partnerships with the CDC, American Red Cross, Carter Center, and Children's Healthcare of Atlanta. Analysis of her 2023-2025 publications reveals intensifying focus on eradication program modeling for polio and Guinea worm, with increasing integration of machine learning for predictive accuracy in vaccine distribution. A pronounced trend addresses health equity through targeted interventions for under-immunized populations in Sub-Saharan Africa, emphasizing resource allocation under constraints and cross-border coordination challenges. Her scientific recognition includes: INFORMS Fellow (2015) NSF CAREER Award (2001) Outstanding Professional Education Award, Georgia Tech (2018) Denning Award for Global Engagement, Georgia Tech (2016) Women in Engineering Excellence Teaching Award (2005) Moving Spirit Award, INFORMS (2005) Dr. Keskinocak has secured extensive project funding through collaborations with federal agencies and NGOs, directing research on pandemic response systems, vaccine logistics, and disaster debris management. While specific advisees aren't publicly cataloged, her leadership in the Center for Health and Humanitarian Systems mentors numerous graduate researchers through interdisciplinary projects. She significantly influences national policy via National Academies committees addressing supply chain resilience and vaccine distribution infrastructure. The Center for Health and Humanitarian Systems operates as a dynamic hub where engineering rigor meets humanitarian action, coordinating multi-institutional teams to develop deployable solutions for global health crises and disaster response systems.

• Health Systems
• Humanitarian Systems
• Supply Chain Management
• +۵ مورد دیگر

Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.

• Microbiology
• Infectious Diseases
• Cell Biology
• +۷ مورد دیگر

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

• Mass Spectrometry
• Proteomics
• Systems Biology
• +۶ مورد دیگر

Prof. Knut Drescher is an Associate Professor at the Biozentrum, University of Basel , leading a research group focused on bacterial biofilms , swarming , and microbial multicellularity . Previously, he served as a Professor of Biophysics and Max Planck Research Group Leader at Philipps-Universität Marburg (2015-2021) and conducted postdoctoral research at Princeton University. Research Interests: Physical and biological mechanisms of biofilm formation Cell-cell interactions in microbial communities Antibiotic resistance in biofilms Hydrodynamics of bacterial swarms Evolution of cooperation in multispecies biofilms Development of bioimaging software (BiofilmQ, BacStalk) Scientific Awards: 2023: SNSF Consolidator Grant 2019: Heinz Maier-Leibnitz Prize (DFG), VAAM Research Prize, IUPAP Young Scientist Prize 2016: ERC Starting Grant Advising & Grants: Advises PhD and Master's students in microbiology, biophysics, and bioinformatics Secured major grants from ERC , HFSP , and DFG

• Bacterial Biofilms
• Microbial Multicellularity
• Biophysics
• +۵ مورد دیگر

Professor David Grainger is a faculty member at the University of Birmingham's School of Biosciences, specializing in Molecular Microbiology. He leads the Grainger Lab, focusing on bacterial chromosome biology, pathogenicity, and antibiotic resistance. His research integrates high-throughput techniques and single-molecule analysis to study gene regulation and bacterial pathogenesis. Education: PhD (2004), PGCE (2000), BSc (1999) in Biochemistry from the University of Birmingham. Affiliations: Part of the Institute of Microbiology and Infection (IMI), collaborating with experts in genomics, proteomics, and structural biology. Research Interests: Deciphering chromosome biology of pathogenic bacteria, including transcriptional regulation, toxin production control, and antibiotic resistance pathways. Utilizes cutting-edge methods like Hi-C for 3D chromatin analysis and single-molecule microscopy. Recent Articles: Focused on transposon capture mechanisms, bacterial promoter diversity, and quorum sensing signaling. Highlights include studies on Salmonella regulons and Vibrio cholerae biofilm suppression. Awards: Wellcome Trust Career Development Fellowship (2008), Runner-up in 'Science Snaps' competition for scientific communication. Grants: Career Development Fellowship-funded establishment of his research group at the University of Warwick (2008). Labs/Teams: Grainger Lab at the University of Birmingham, part of the IMI network. Engages in public science outreach via Twitter and lab website.

• Bacterial Chromosome Biology
• Pathogenicity
• Antibiotic Resistance Mechanisms
• +۳ مورد دیگر

Professor Francis Butler is a Full Professor at University College Dublin's School of Biosystems and Food Engineering, where he has been since 1990. His academic roles include research leadership in food safety, food chain integrity, and microbial risk assessment. He leads the UCD Institute for Food and Health and the UCD Centre for Food Safety as a Principal Investigator. Education: BE, Grad Dip University Teaching & Learning, MBA, and PhD from University College Dublin. Research Focus: His work centers on food safety hazards, quantitative risk assessment, and next-generation sequencing for pathogen identification. Recent projects include Listeria monocytogenes growth modeling, norovirus in oysters, and hepatitis E in pork products. He has secured over €6 million in research grants, including EU-funded projects like FOODINTEGRITY and SIGMACHAIN. Awards & Recognition: European Food Safety Authority Fellowship, Marie Sklodowska-Curie Fellowship, and UCD Teaching Grant. He coordinates international educational programs, including the UCD MSC Food Safety and Risk Analysis. Professional Activities: Member of EFSA advisory committees, editorial boards (e.g., Microbial Risk Analysis ), and international conference chairs. His work bridges academia, industry, and policy to enhance food safety standards globally.

• Food Safety
• Food Chain Integrity
• Microbiological Risk Assessment
• +۶ مورد دیگر